Radioliant Technology Licenses Radiopharmaceutical to South Korea for $571.5 Million

On July 17, 2024, a major collaboration in the field of global medical technology took place. China's leading radiation therapy company, Hulian Technology, has signed a global licensing agreement worth $571.5 million with South Korean biotech giant SKBiopharmaceuticals, marking a solid step in the two companies' collaboration in the field of cancer treatment.

Under the terms of the agreement, SKBiopharmaceuticals will receive exclusive rights to develop, manufacture and commercialize FL-091, a radiopharmaceuticals developed by Radiopharmaceuticals for NTSR1-positive cancers. FL-091 is an innovative small molecule radioligand carrier whose high NTSR1-binding affinity and excellent antitumor activity demonstrated in preclinical studies has brought new hope for cancer therapy.

This cooperation stems from the deep accumulation and shared vision of the two companies in their respective fields. As a global emerging force in the field of radiation therapy, Fulian Technology has won wide recognition in the industry with its innovative capabilities in nuclear drug development and positive results in preclinical research. SKBiopharmaceuticals, as a leader in Korean biotechnology, has strong global marketing and commercialization capabilities, and this cooperation will undoubtedly accelerate the application and promotion of FL-091 and its derivatives on a global scale, bringing more effective treatment options to cancer patients around the world.

This cooperation not only reflects the important position of the two companies in the global medical technology field, but also indicates that the application of radiation therapy in cancer treatment will enter a new stage. With the continuous progress of science and technology, we have reason to believe that more innovative therapies will emerge in the future, bringing better treatment results and quality of life for cancer patients around the world.

In the future, Hulian Technology will continue to uphold the spirit of innovation and focus on the research and development of radiation therapy, with a view to making greater contributions to improving the prognosis of cancer patients and improving the quality of life. This cooperation with SKBiopharmaceuticals has undoubtedly injected strong impetus into the realization of this goal.